TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06681415
Drug: Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding albumin to the priming solution can help reduce hemodilution and consequent extracardiac complications by maintaining colloid oncotic pressure. Albumin helps counteract the intravascular fluid shift to the extravascular space and reduces the risk of complications associated with fluid imbalance.~Postoperative pulmonary complications following CPB can significantly impact postoperative outcomes. Patients developing PPC have prolonged mechanical ventilation, extended hospitalisation, longer ICU stays, and elevated postoperative mortality. One of the most common PPCs following CPB is pleural effusion.~Our primary objective was to evaluate the effectiveness of adding 100 ml of 20% human albumin to the CPB priming solution compared to standard priming, with a specific focus on its potential role in reducing the occurrence of pleural effusion.
Study: NCT05146869
Drug: DBPR108 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.
Study: NCT05249790
Drug: Recommended treatment schedule
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAiDs), Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
Study: NCT05249790
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimens different from the recommended one according to family physician personal practice
Study: NCT06684106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo together with statin in ASCVD patients
Study: NCT05555589
Drug: RGN-259
Approvals — FDA: no, EMA: no, PMDA: no
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
Study: NCT05555589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
Study: NCT06709885
Drug: CapeOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; Day1-Day14, capecitabine, 850-1000mg/m2, BID, PO. ） Post-operation 4 cycles of Capeox
Study: NCT06708767
Drug: Contrast Media
Normalized name: CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV contrast media administration
Study: NCT06708767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT05376943
Drug: Direct Acting Antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
Study: NCT05231668
Drug: SAR439459
Normalized name: MAB HUMAN (IGG4) ANTI P01137 (TGFB1_HUMAN) OR ANTI P61812 (TFGB2_HUMAN) OR ANTI P10600 (TGFB3_HUMAN)(SAR439459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for solution for infusion; IV infusion
Study: NCT05231668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion; IV infusion
Study: NCT05785611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT05351801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06461286
Drug: PYC-001
Normalized name: PYCNANTHUS ANGOLENSIS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Group Assignment
Study: NCT04821856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT oil and flavoring solution, also manufactured by THC Pharma
Study: NCT00001128
Drug: Paromomycin sulfate
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001128
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05721222
Drug: PRO1160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of PRO1160
Study: NCT05068024
Drug: FWD1509 MsOH
Approvals — FDA: no, EMA: no, PMDA: no
Description: FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.
Study: NCT05852938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
Study: NCT05252078
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.
Study: NCT05174845
Drug: 1L PEG + ASCORBIC ACID
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 2-Day Split-Dosing: The patient has taken the product in the evening before the scheduled colonoscopy and mandatory additional clear fluid. The patient has taken the second dose with mandatory additional clear fluids on the morning of the colonoscopy.~* Same Day: The patient has taken the first dose of the product on the day of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break, the patient has taken a second dose plus additional clear mandatory fluid.
Study: NCT05059587
Drug: MBA-P01
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBA-P01 will be injected into the Glabellar line.
Study: NCT06063772
Drug: Lactated Ringers, Intravenous
Normalized name: Lactated Ringers, Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90s to a maximum rate 32mg/hr for clevidipine or the volume equivalent of placebo.
Study: NCT05022849
Drug: Bridging Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.
Study: NCT05053152
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06098079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
Study: NCT06076291
Drug: SG1827
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhaseⅠa will use an accelerated titration and Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.02mg/kg, 0.2mg/kg, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg, and 15mg/kg by IV infusion. Accelerated titration (1 patient) will be only applied to the first cohort.
Study: NCT06356311
Drug: Trifluridine-Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.
Study: NCT05464173
Drug: endocrinotherapy（doctor's choice）
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the drug insert
Study: NCT06356311
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
Study: NCT05000697
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 5FU during the consolidation chemotherapy after long course chemoradiation
Study: NCT00775476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (sugar) twice daily, daily dosage will match that of NAC that was tolerated between daily dosages of 2.4 g and 4.8 g during the open-label titration phase.
Study: NCT04872218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 week treatment of IV placebo following recommended dosages from the abatacept monograph
Study: NCT05815719
Drug: Urinary Human follicle stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable dose.
Study: NCT05483933
Drug: Pegylated Liposomal Doxorubicin + SL-172154
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study: NCT06511895
Drug: AZD4205
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4205 capsules administered at 150 mg or 75 mg orally, once daily, in 28-day cycle.
Study: NCT03999853
Drug: BKR-017
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKR-017
Study: NCT05650242
Drug: BA1106
Approvals — FDA: no, EMA: no, PMDA: no
Description: In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W).
Study: NCT05555758
Drug: Adamgammadex Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aom0319 will be administered intravenously with water for injection.
Study: NCT05401812
Drug: Intravenous glucocorticoid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone, dexamethasone, or methylprednisolone
Study: NCT04523142
Drug: CyclASol Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A solution in vehicle
Study: NCT06057454
Drug: R-5280
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Superior Starch
Study: NCT05501912
Drug: ABM-1310
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation starting dose will be based on a priming dose one level below the highest safe dose or two levels below the MTD that has been tested in US clinical trials.~Dose expansion will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level.
Study: NCT06049667
Drug: NTQ2494 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria.~For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle).~Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle).
Study: NCT05773703
Drug: PSMA-Targeted [In-111]-Labeled Trillium Compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotracer
Study: NCT06378983
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin
Study: NCT04623398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05298306
Drug: LAT8881
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part A, LAT8881 will be given as a single intravenous infusion at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, a single intravenous infusion of LAT8881 will be given, the dose to be determined by the results in Part A
Study: NCT05298306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo'given as a single intravenous infusion at all dose levels
Study: NCT05331300
Drug: LASN01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating single and multiple doses of LASN01
Study: NCT05331300
Drug: LASN01
Approvals — FDA: no, EMA: no, PMDA: no
Description: LASN01 will be administered intravenously
Study: NCT05331300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of matching placebo
Study: NCT05331300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously
Study: NCT06356714
Drug: Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens
Normalized name: Spongia officinalis skeleton extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocardia Rubra Cell Wall Skeleton 200 mcg-400 mcg, 0.3 ml diluted in water for injection or lidocaine, was injected subcutaneously every 2 or 3 weeks.~Efficacy was evaluated every 2 cycles according to RECIST 1.1 criteria. Patients are enrolled and given this study regimen of drugs on top of their prior second- or third-line regimen until disease progression or intolerable toxicities occur; or the patient requests to be discharged.
Study: NCT06427343
Drug: High-dose ferric derisomaltose
Normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After baseline assessment, participants will be randomized in a 1:1 ratio to receive a high-dose IV iron regimen and a low-dose IV iron regimen. After the initial iron repletion, ferritin concentration and TSAT were measured every three months and the results used to determine the dose of ferric derisomaltose during follow-up.~In the high-dose group, participants will receive repeat iron dosing as long as the serum ferritin was not \>700 ng/mL, or if TSAT was not \>40% during follow-up.
Study: NCT06427343
Drug: Low-dose ferric derisomaltose
Normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the low-dose group, participants will receive repeat iron dosing if ferritin \<100 ng/mL or if ferritin 100-300 ng/mL and TSAT \>20% during follow-up.
Study: NCT04755322
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg
Study: NCT05625412
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06342778
Drug: Doxylamine + Pyridoxine
Normalized name: doxylamine / pyridoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of R or T drug in each of 2 periods of the study under fed conditions
Study: NCT05314569
Drug: Fentanyl- midazolam
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam is known to have potential anti-inflammatory effects and antioxidant activity. They have been proven to provide protective effects for patients who underwent cardiac surgery.Fentanyl is one opioid that has been closely linked to inflammatory mediators and myocardial protection. It reduces the CPB-induced inflammatory response and ischaemic reperfusion injury during cardiac surgery
Study: NCT06528249
Drug: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
Normalized name: ACELLULAR TISSUE ENGINEERED VESSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
Study: NCT06172127
Drug: Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
Normalized name: Phesgo 1,200 MG / 600 MG / 30,000 UNT per 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.
Study: NCT06172127
Drug: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Normalized name: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 10 mL solution of 600 mg of pertuzumab and 600 mg of trastuzumab.
Study: NCT05222529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
Study: NCT04964843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04752722
Drug: EG-70 (phase 1)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.
Study: NCT05631899
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
Study: NCT05215990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive placebo drug with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
Study: NCT04752722
Drug: EG-70 (phase 2)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive during Treatment Period, up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.
Study: NCT06335134
Drug: XW003 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT06335134
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT04996017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
Study: NCT06447987
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05270213
Drug: RBS2418
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
Study: NCT04886284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo
Study: NCT04932512
Drug: ION224
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION224 will be administered by SC injection.
Study: NCT04597008
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed immediately before wound closure.
Study: NCT04597008
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed immediately before wound closure.
Study: NCT05281562
Drug: L-Arginine Powder
Normalized name: L-Arginine powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 4.5 grams L-Arginine, powder form.
Study: NCT06589830
Drug: TL938 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06613893
Drug: Inhalational anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia will be maintained with inhaled isoflurane, Iso-MAC from (0.7 to 1.4%)(Hawkley, Preston, and Maani 2018) and fentanyl 0.35 to 0.5 mcg/kg supplementary dose will be given if needed to maintain the heart rate and blood pressure within the range of ±20% of the baseline
Study: NCT06707194
Drug: Benzathine Penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, 1.2 million units of intramuscular injection, once every two weeks
Study: NCT05165225
Drug: Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m\^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m\^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m\^2 d1 iv Q3W for 4 cycles
Study: NCT06337422
Drug: Celecoxib 200 mg capsule
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 mg capsule
Study: NCT04732169
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes
Study: NCT04754243
Drug: Standard protocol in IUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giving patients gonadotropins without antagonist cetrotide
Study: NCT04705909
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in this group will receive placebo tablets concomitantly with the intended chemotherapy for the treatment period prior to surgery.
Study: NCT06556641
Drug: GZR33 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as once daily subcutaneous dose
Study: NCT06556641
Drug: GZR101 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as once daily subcutaneous dose
Study: NCT06556641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as once daily subcutaneous dose